| Labcorp

March 24, 2022

De-Risk Your Drug Development: CMC Manufacturing

This brochure introduces the potential for problems at BLA submission where a recent analysis of FDA complete response letters showed that 47% of the products that received them had CMC analytical issues. In many cases the drug had shown sufficient evidence of clinical efficacy but was delayed entering the market due to issues with the CMC package.

March 27, 2022

How Well Do Defined Approaches Predict the Human Skin Sensitisation Potential of Previously Untested Chemicals?

SOT 2022 -- The in vitro prediction of human skin sensitisation took a significant step forward with the publication of the OECD's Health Effects Guideline 497 on Defined Approaches for Skin Sensitisation in 2021.

March 29, 2022

Achieving Sponsor Goals with Efficient End-to-End Solutions

Through a comprehensive range of solutions, efficient end-to-end services and connections with international regulatory agencies, we help build your program with a sound regulatory strategy, optimal trial design and compliance with global submission requirements.

March 31, 2022

Regulatory Revolution in Biopesticides

April 8, 2022

Comprehensive Cell- and Gene-Based Tumor Profiling Using Flow Cytometry and NanoString in a Murine Bladder Cancer Model

AACR 2022 -- Bladder cancer (BC) is the thirteenth leading cause of cancer-related deaths. Five checkpoint immunotherapies that target the PD-1/PD-L1 axis are FDA approved, and gene- and protein-based approaches are helping to identify new combination treatment strategies for therapeutic intervention.

<span>Chimeric Antigen Receptor (CAR) T Cell Generation for Therapeutic Testing in the Disseminated NALM6-Luc Human B-Cell Acute Lymphoblastic Leukemia Model</span>

April 8, 2022

Chimeric Antigen Receptor (CAR) T Cell Generation for Therapeutic Testing in the Disseminated NALM6-Luc Human B-Cell Acute Lymphoblastic Leukemia Model

AACR 2022 -- T cells engineered to express Chimeric Antigen Receptors (CARs) through transduction with a lentiviral vector represent an effective strategy to specifically eliminate cancerous cells from a patient. Anti-CD19 single chain variable fragment (ScFv) is the extracellular, antigen-binding domain.

April 8, 2022

Reconstructed Plate-Based 3D Screening Assays That Predict In Vivo Responses

AACR 2022 -- Labcorp has employed 3D model systems co-developed with zPREDICTA to create preclinical models to address the increasing relevance of 3D in vitro models. These organ-specific models support tumor cell growth and mimic the composition and architecture of both solid tumors and hematological malignancies.

April 8, 2022

Model Characterization and Tumor Immune Profile Assessment for Syngeneic RM-1 Murine Prostate Cancer in Male C57BL/6 Mice

AACR 2022 -- Syngeneic mouse tumor models are widely used to demonstrate activity of novel anti-cancer immunotherapies. RM-1 is a murine prostate cancer cell line derived from a Ras/Myc-induced prostate cancer that grows aggressively, is nonimmunogenic and androgen independent.

April 8, 2022

Systematic Evaluation of Cloudman S91 and YUMM1.7 Murine Melanoma Models to Immunotherapy and Focal Radiation

AACR 2022 -- In the preclinical oncology setting, the B16-F10 syngeneic melanoma model is commonly used but is highly refractory to most immunomodulators, limiting the applicability of this model.

April 19, 2022

Introducing the Delivery Director

The Delivery Director role is a key component of the Labcorp Drug Development Operating Model for clinical trials. One is assigned to each trial and is a senior leader who improves the delivery through experience, insight and connections within the business.

Managing Your Health

Diseases & Specialties

Treatment Methods & Product Testing

Lab Disciplines & Services

De-Risk Your Drug Development: CMC Manufacturing

How Well Do Defined Approaches Predict the Human Skin Sensitisation Potential of Previously Untested Chemicals?

Achieving Sponsor Goals with Efficient End-to-End Solutions

Regulatory Revolution in Biopesticides

Comprehensive Cell- and Gene-Based Tumor Profiling Using Flow Cytometry and NanoString in a Murine Bladder Cancer Model

Chimeric Antigen Receptor (CAR) T Cell Generation for Therapeutic Testing in the Disseminated NALM6-Luc Human B-Cell Acute Lymphoblastic Leukemia Model

Reconstructed Plate-Based 3D Screening Assays That Predict In Vivo Responses

Model Characterization and Tumor Immune Profile Assessment for Syngeneic RM-1 Murine Prostate Cancer in Male C57BL/6 Mice

Systematic Evaluation of Cloudman S91 and YUMM1.7 Murine Melanoma Models to Immunotherapy and Focal Radiation

Introducing the Delivery Director